ECSP21044662A - Gen suicida - Google Patents
Gen suicidaInfo
- Publication number
- ECSP21044662A ECSP21044662A ECSENADI202144662A ECDI202144662A ECSP21044662A EC SP21044662 A ECSP21044662 A EC SP21044662A EC SENADI202144662 A ECSENADI202144662 A EC SENADI202144662A EC DI202144662 A ECDI202144662 A EC DI202144662A EC SP21044662 A ECSP21044662 A EC SP21044662A
- Authority
- EC
- Ecuador
- Prior art keywords
- tnf
- alpha
- cells
- mutants
- individual
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 4
- 239000012528 membrane Substances 0.000 abstract 2
- 238000011467 adoptive cell therapy Methods 0.000 abstract 1
- 230000004540 complement-dependent cytotoxicity Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/35—Cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/25—Suicide switch
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862769405P | 2018-11-19 | 2018-11-19 | |
| US201862773372P | 2018-11-30 | 2018-11-30 | |
| US201962791464P | 2019-01-11 | 2019-01-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21044662A true ECSP21044662A (es) | 2021-09-30 |
Family
ID=68848450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202144662A ECSP21044662A (es) | 2018-11-19 | 2021-06-18 | Gen suicida |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220023343A1 (enExample) |
| EP (1) | EP3883959A1 (enExample) |
| JP (1) | JP2022513099A (enExample) |
| KR (1) | KR20210093977A (enExample) |
| CN (1) | CN113272320A (enExample) |
| AU (1) | AU2019384115A1 (enExample) |
| BR (1) | BR112021009634A2 (enExample) |
| CA (1) | CA3120349A1 (enExample) |
| CL (1) | CL2021001300A1 (enExample) |
| CO (1) | CO2021007824A2 (enExample) |
| EC (1) | ECSP21044662A (enExample) |
| IL (1) | IL283242A (enExample) |
| MX (1) | MX2021005847A (enExample) |
| PE (1) | PE20211236A1 (enExample) |
| PH (1) | PH12021551142A1 (enExample) |
| SG (1) | SG11202105238YA (enExample) |
| TW (1) | TW202039538A (enExample) |
| WO (1) | WO2020106619A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL311837A (en) | 2021-10-20 | 2024-05-01 | Takeda Pharmaceuticals Co | Compositions targeting bcma and methods of use thereof |
| EP4493581A1 (en) * | 2022-03-18 | 2025-01-22 | University of Rochester | Combination therapy for treatment of cancer, methods and systems of delivery thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3817955A1 (de) | 1988-05-27 | 1989-11-30 | Hoechst Ag | Tnf-inhibitor enthaltendes arzneimittel |
| US6143866A (en) | 1989-07-18 | 2000-11-07 | Amgen, Inc. | Tumor necrosis factor (TNF) inhibitor and method for obtaining the same |
| WO1994000555A2 (en) * | 1992-06-25 | 1994-01-06 | Cetus Oncology Corporation | Compositions for the inhibition of protein hormone formation and uses thereof |
| US20040121971A1 (en) * | 2002-12-20 | 2004-06-24 | Gang Chen | Therapeutic use of tumor necrosis factor-alpha mutein |
| JPWO2005035586A1 (ja) * | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JP5956982B2 (ja) * | 2010-05-27 | 2016-07-27 | メルク・シャープ・エンド・ドーム・コーポレイション | 改善された特性を有する抗体の製造方法 |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| EP4166148B1 (en) * | 2014-06-06 | 2026-02-18 | Memorial Sloan-Kettering Cancer Center | Mesothelin-targeted chimeric antigen receptors and uses thereof |
| EA035898B1 (ru) * | 2014-10-03 | 2020-08-28 | НАНОТИКС, ЭлЭлСи | Композиции и способы для ингибирования биологической активности растворимых биомолекул |
| AU2016306209B2 (en) * | 2015-08-07 | 2023-07-06 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific CAR T-cells for solid tumor targeting |
| KR20240024328A (ko) * | 2016-11-22 | 2024-02-23 | 알로플렉스 바이오테라퓨틱스 | 동종이형 종양 세포 백신 |
| CN107365798B (zh) * | 2017-07-13 | 2020-07-14 | 山东省齐鲁细胞治疗工程技术有限公司 | 一种携带iCasp9自杀基因的CD19-CAR-T细胞及其应用 |
| CN107245106B (zh) * | 2017-07-18 | 2020-06-12 | 深圳市免疫基因治疗研究院 | 一种基于cd10的嵌合抗原受体及其应用 |
| CN107337737B (zh) * | 2017-07-18 | 2020-02-07 | 深圳市免疫基因治疗研究院 | 一种嵌合抗原受体及其应用 |
| CN107245107B (zh) * | 2017-07-18 | 2020-02-07 | 深圳市免疫基因治疗研究院 | 一种基于cd20的嵌合抗原受体及其应用 |
| CN107312098B (zh) * | 2017-07-18 | 2020-06-12 | 深圳市免疫基因治疗研究院 | 一种基于cd22的嵌合抗原受体及其应用 |
| CN107312097B (zh) * | 2017-07-18 | 2020-06-16 | 深圳市免疫基因治疗研究院 | 一种基于cd30的嵌合抗原受体及其应用 |
| CN107400168B (zh) * | 2017-07-18 | 2020-02-07 | 深圳市免疫基因治疗研究院 | 一种基于cd117的嵌合抗原受体及其应用 |
-
2019
- 2019-11-18 KR KR1020217018726A patent/KR20210093977A/ko not_active Ceased
- 2019-11-18 US US17/309,315 patent/US20220023343A1/en not_active Abandoned
- 2019-11-18 CN CN201980086243.2A patent/CN113272320A/zh active Pending
- 2019-11-18 JP JP2021527926A patent/JP2022513099A/ja active Pending
- 2019-11-18 SG SG11202105238YA patent/SG11202105238YA/en unknown
- 2019-11-18 WO PCT/US2019/062009 patent/WO2020106619A1/en not_active Ceased
- 2019-11-18 CA CA3120349A patent/CA3120349A1/en active Pending
- 2019-11-18 AU AU2019384115A patent/AU2019384115A1/en not_active Abandoned
- 2019-11-18 EP EP19818397.2A patent/EP3883959A1/en not_active Withdrawn
- 2019-11-18 BR BR112021009634-5A patent/BR112021009634A2/pt not_active IP Right Cessation
- 2019-11-18 PE PE2021000739A patent/PE20211236A1/es unknown
- 2019-11-18 MX MX2021005847A patent/MX2021005847A/es unknown
- 2019-11-19 TW TW108141960A patent/TW202039538A/zh unknown
-
2021
- 2021-05-18 CL CL2021001300A patent/CL2021001300A1/es unknown
- 2021-05-18 IL IL283242A patent/IL283242A/en unknown
- 2021-05-19 PH PH12021551142A patent/PH12021551142A1/en unknown
- 2021-06-15 CO CONC2021/0007824A patent/CO2021007824A2/es unknown
- 2021-06-18 EC ECSENADI202144662A patent/ECSP21044662A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210093977A (ko) | 2021-07-28 |
| CL2021001300A1 (es) | 2022-03-18 |
| MX2021005847A (es) | 2021-09-23 |
| IL283242A (en) | 2021-07-29 |
| SG11202105238YA (en) | 2021-06-29 |
| EP3883959A1 (en) | 2021-09-29 |
| PE20211236A1 (es) | 2021-07-09 |
| TW202039538A (zh) | 2020-11-01 |
| CO2021007824A2 (es) | 2021-06-30 |
| WO2020106619A1 (en) | 2020-05-28 |
| US20220023343A1 (en) | 2022-01-27 |
| PH12021551142A1 (en) | 2021-10-25 |
| CN113272320A (zh) | 2021-08-17 |
| CA3120349A1 (en) | 2020-05-28 |
| JP2022513099A (ja) | 2022-02-07 |
| BR112021009634A2 (pt) | 2021-08-10 |
| AU2019384115A1 (en) | 2021-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
| CO2021006365A2 (es) | Composiciones y métodos para expresar el factor ix | |
| BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
| BRPI0812091A2 (pt) | Método para fabricar uma proteína policlonal recombinante | |
| MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
| MX2019012017A (es) | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. | |
| ECSP21044662A (es) | Gen suicida | |
| EA202090931A2 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| EP4286511A3 (en) | Method to treat cancer with engineered t-cells | |
| NZ725201A (en) | Improved methods for manufacturing adoptive cell therapies | |
| EA201892588A1 (ru) | Прямой отбор клеток, экспрессирующих высокие уровни гетеромерных белков, с использованием глутаминсинтетазных векторов внутригенной комплементации | |
| EP4188442A4 (en) | COMPOSITIONS CONTAINING EX-VIVO-DEPLEATED T CELLS WITH MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | |
| MX2016006511A (es) | Animales no humanos que tienen un gen del factor activador de celulas b. | |
| MY172618A (en) | Mice that make binding proteins comprising vl domains | |
| MX2015012875A (es) | Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos. | |
| MX2012011636A (es) | Anticuerpo que reconoce el factor inhibidor de la leucemia humana (lif) y uso de anticuerpos anti-lif en eltratamiento de enfermedades asociadas a una proliferacion celulara no deseada. | |
| BR112022003852A2 (pt) | Métodos de preparação de células t para terapia de células t | |
| MX2017005925A (es) | Metodos de producción de proteínas de cadena doble en bacterias. | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
| MX2018012629A (es) | Diferenciacion de celulas madre pluripotentes a celulas de endodermo intestinal del intestino medio. | |
| EP4373501A4 (en) | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy | |
| BR112016027797A2 (pt) | métodos e meios de cultura de células compreendendo n-acetilcisteína | |
| MX2016014718A (es) | Cocultivo de propionibacteria y levadura. | |
| EP4069831A4 (en) | Genetically engineered double negative t cells as an adoptive cellular therapy | |
| MX382810B (es) | Mejora del metabolismo de microalga de xilosa. |